Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE-extension open-label extension study of ralinepag in pulmonary arterial hypertension
MOH_2019-06-30_004800Phase 3Active, not recruiting
- Sponsor
- United Therapeutics Corporation
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ralinepag in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Primary endpoint: Long-term safety and tolerability of ralinepag. Started Dec 2018; status: active, not recruiting.
02
Drugs
ralinepag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2019-06-30_004800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-30_004800.